Treatment of Acute Myeloblastic Leukemia in Younger Patients

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

study of the value of the cytogenetics and the monitoring of the residual minimum disease in the standard treatment of acute myeloblastic leukemia.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PETHEMA Foundation

Criteria

Inclusion Criteria:

• Age< or =65 years.

• ECOG<=3.

• AML of new diagnose.

• Consent for chemotherapy.